AB Science SA (Euronext - FR0010557264 - AB) today announced that a confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer (study AB22007) has been authorized by FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback